At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Magnesium citrate, tribasic anhydrous soft gelatin capsule +1 moredrug
Likely dose
Magnesium citrate, tribasic anhydrous soft gelatin capsule 110 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of RMJH-111b in Adult Subjects With Essential Hypertension
In Brief
A Phase 2 clinical trial evaluating Magnesium citrate, tribasic anhydrous soft gelatin capsule and Placebo soft gelatin capsule for Essential Hypertension. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension. The study also measured the amount of magnesium in the blood and urine before and after RMJH-111b administration to evaluate what the body does to RMJH-111b (pharmacokinetics).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedJul 2016
Primary CompletionJul 2016
TodayJul 2026
First PostedJul 4, 2016
Enrollment StartJun 10, 2016
Primary CompletionJul 7, 2016
TodayJul 2, 2026
Enrollment to primary: 27 daysPosted 10.0 years ago
Interventions
Magnesium citrate, tribasic anhydrous soft gelatin capsuledrug
110 mg elemental magnesium/capsule
Placebo soft gelatin capsuledrug
0 mg elemental magnesium/capsule